Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient
- 570 Downloads
Conflicts of interest
The study was not funded. Dr. Piscolla has nothing to disclose. Dr. Hakiki receives research support from Merck Serono, Novartis and Teva. Dr. Pastò has nothing to disclose. Dr. Razzolini has received research support from Novartis. Dr. Portaccio serves on a scientific advisory board for Biogen-Idec, Merck Serono and Bayer, received honoraria for speaking from Biogen-Idec and Teva, and receives research support from Merck Serono, Biogen-Idec, Bayer Schering and Sanofi Aventis. Dr. Amato serves on scientific advisory boards for Biogen-Idec, Merck Serono, Bayer Schering and Sanofi Aventis and receives research support and honoraria for speaking from Biogen-Idec, Merck Serono, Bayer Schering and Sanofi Aventis.
The patient was fully informed and agreed upon the publication of the report in accordance with the ethical standards laid down in the 1964 Helsinki declaration and its amendments.
- 4.De Vera A, Kappos L, Zhang-Auberson L et al (2010) Pooled efficacy data demonstrate that fingolimod reduces multiple sclerosis relapse rate with no evidence of rebound after discontinuing treatment. Mult Scler 16(supplement 10):S 295Google Scholar